Melanotan I (afamelanotide)
Afamelanotide · Melanotan-1
Melanotan I is a name associated with afamelanotide, an alpha-MSH analogue. It is not Melanotan II, and the distinction extends beyond the number in the name.
Reviewed September 2026
- Residues
- 13. verified: 13 peptide-chain residues; modifications and any counterion are not extra residues.
- Average mass
- 1,646.8 Da. verified: Reference form: Afamelanotide/Melanotan I reference N-acetylated, C-terminally amidated peptide containing norleucine and D-Phe; acetate is excluded.; formula C78H111N21O19. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 13 |
|---|---|
| Average mass | 1,646.8 Da |
| pI | Not established |
| Aliases | Afamelanotide, Melanotan-1 |
|---|---|
| Research area | Endocrine |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Afamelanotide/Melanotan I reference N-acetylated, C-terminally amidated peptide containing norleucine and D-Phe; acetate is excluded. Reference only, not a sold-lot measurement.
- Residues: 13 (verified). 13 peptide-chain residues; modifications and any counterion are not extra residues. Residues source 1
- Average mass: 1,646.8 Da (verified). Reference form: Afamelanotide/Melanotan I reference N-acetylated, C-terminally amidated peptide containing norleucine and D-Phe; acetate is excluded.; formula C78H111N21O19. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Melanotan I. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Afamelanotide for Erythropoietic Protoporphyria. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Melanotan I (afamelanotide)
Identity and context
This entry concerns the afamelanotide reference identity. The chemical specification of the catalogue material still requires confirmation, including substitutions and terminal groups. A study of a defined afamelanotide implant does not identify the contents of a separate research vial.
Reference classification
Modified peptide. The linked catalogue product is Melanotan I. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm afamelanotide identity with a complete structural specification rather than relying on the Melanotan I trade name alone. Do not borrow molecular data from the cyclic Melanotan II analogue.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | Two randomized trials studied afamelanotide implants in people with erythropoietic protoporphyria, measuring pain-free sunlight exposure and related outcomes. That disease-specific context is essential to interpreting the results; it is not a study of cosmetic tanning in otherwise healthy users. | Source context |
| What cannot be inferred | The results do not validate an unrelated preparation or establish that the catalogue product shares the properties, quality controls or status of the trial formulation. No self-administration guidance follows from this reference. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Afamelanotide for Erythropoietic ProtoporphyriaPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.